SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

FRASSOLDATI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.644
AS - Asia 3.556
EU - Europa 2.005
SA - Sud America 680
AF - Africa 76
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 3
Totale 13.975
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.494
SG - Singapore 1.531
CN - Cina 926
BR - Brasile 586
IT - Italia 422
DE - Germania 408
HK - Hong Kong 376
GB - Regno Unito 215
VN - Vietnam 206
PL - Polonia 195
TR - Turchia 192
UA - Ucraina 166
SE - Svezia 140
RU - Federazione Russa 107
FI - Finlandia 103
ID - Indonesia 93
MX - Messico 85
IN - India 66
CA - Canada 49
NL - Olanda 46
BE - Belgio 39
ZA - Sudafrica 36
JP - Giappone 35
AR - Argentina 33
AT - Austria 32
FR - Francia 28
BD - Bangladesh 24
ES - Italia 23
IQ - Iraq 21
CZ - Repubblica Ceca 15
EC - Ecuador 12
LT - Lituania 12
CL - Cile 11
IE - Irlanda 11
PY - Paraguay 11
AU - Australia 10
PE - Perù 10
PK - Pakistan 10
MA - Marocco 9
UZ - Uzbekistan 9
CO - Colombia 8
EG - Egitto 7
KR - Corea 7
SA - Arabia Saudita 7
AL - Albania 6
CH - Svizzera 6
DZ - Algeria 6
IR - Iran 6
IL - Israele 5
JO - Giordania 5
LV - Lettonia 5
RO - Romania 5
VE - Venezuela 5
CR - Costa Rica 4
KE - Kenya 4
KZ - Kazakistan 4
PA - Panama 4
PT - Portogallo 4
TN - Tunisia 4
CI - Costa d'Avorio 3
HU - Ungheria 3
KG - Kirghizistan 3
NO - Norvegia 3
OM - Oman 3
PS - Palestinian Territory 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
AZ - Azerbaigian 2
BG - Bulgaria 2
ET - Etiopia 2
JM - Giamaica 2
LB - Libano 2
MY - Malesia 2
NP - Nepal 2
PH - Filippine 2
QA - Qatar 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
CG - Congo 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GR - Grecia 1
IM - Isola di Man 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
Totale 13.970
Salva come PNG Salva come JPEG
Città #
Fairfield 868
Singapore 812
Ashburn 807
Woodbridge 751
Houston 465
Chandler 416
Santa Clara 386
Hong Kong 372
Seattle 357
Beijing 337
Wilmington 330
Ann Arbor 321
Cambridge 304
Jacksonville 254
Warsaw 193
Munich 185
Izmir 160
Los Angeles 120
Dallas 117
New York 113
Princeton 104
Nanjing 97
Ferrara 85
Jakarta 82
Ho Chi Minh City 67
Helsinki 61
Shanghai 54
Boardman 52
Mexico City 52
San Diego 51
São Paulo 51
Milan 50
Chicago 48
London 47
The Dalles 41
Brussels 39
Hanoi 39
Nanchang 37
Falls Church 35
Dearborn 32
Hebei 32
Tokyo 31
Columbus 27
Dong Ket 25
Nuremberg 25
Shenyang 25
Tianjin 25
Bologna 23
Redwood City 23
Turku 23
Brooklyn 22
Changsha 22
Orem 22
Stockholm 22
Atlanta 20
Chennai 20
Johannesburg 19
Des Moines 18
Montreal 18
Norwalk 18
Boston 17
Phoenix 17
Bremen 16
Council Bluffs 16
Poplar 16
Buffalo 15
Moscow 15
Rio de Janeiro 15
Belo Horizonte 14
Denver 14
Guangzhou 14
Haiphong 13
Jiaxing 13
Mumbai 13
Vienna 13
Falkenstein 12
Hefei 12
San Francisco 12
Kunming 11
Mountain View 11
Salt Lake City 11
Toronto 11
Addison 10
Manchester 10
Verona 10
Amsterdam 9
Brno 9
Frankfurt am Main 9
Kilburn 9
Pittsburgh 9
Redmond 9
Salvador 9
Tashkent 9
Ankara 8
Campinas 8
Charlotte 8
Dublin 8
Las Vegas 8
Ribeirão Preto 8
Rome 8
Totale 9.711
Salva come PNG Salva come JPEG
Nome #
Absolute quantification of cell-free microRNAs in cancer patients 273
Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR 251
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy 249
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma 247
Gastrointestinal stromal tumors and other malignancies: A case series 235
miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model 222
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study 216
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 216
Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients 213
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy 204
miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models 202
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 192
Current views on anthracycline cardiotoxicity 190
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: Implications for personalised treatment 187
Prevalence of malnutrition in patients at first medical oncology visit: The PreMiO study 187
HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights 181
Synchronous papillary carcinoma and hemangiopericytoma with lung metastases 176
Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study 173
Ovarian endometrioid adenocarcinoma with a yolk sac tumor component in a postmenopausal woman: Case report and review of the literature 168
Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial) 164
The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: How much does it cost? A retrospecive economic assessment from a single-center experience 164
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 163
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion 161
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma 160
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 160
Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy 157
Patient and Health Care Professional Perspectives: A Case Study of the Lung Cancer Integrated Care Pathway 157
Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: A survey among Italian oncologists 156
18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? 154
Il protocollo Diagnostico-Terapeutico e Assistenziale per il carcinoma mammario della Regione Emilia-Romagna. I edizione 154
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab 151
Estrogen receptor mutation: a new strategy to overcome endocrine resistance 139
Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective 138
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 136
Double-blind, placebo-controlled, multicenter, randomized, phase IIB neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 135
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer 134
Changes of biological features in breast cancer cells determined by primary chemotherapy 133
The role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in suspected recovery of breast cancer disease: comparison with Radiological Imaging and impact on patient management 132
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 131
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 131
Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients 129
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 129
Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB) 128
Primary systemic therapy in operable breast cancer: Clinical data and biological fall-out 127
Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study 126
Risk of second cancer in patients with hairy cell leukemia: long-term follow-up 126
Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities? 125
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer 124
Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer 124
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study 124
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: Results of the PerELISA neoadjuvant study 124
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? 123
The role of (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) in patients with breast cancer recurrence: a comparison to conventional imaging (CI) techniques and clinical impact on patient management 123
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results 122
Predictive value of biologic parameters for primary chemotherapy in operable breast cancer 122
Circular RNAs Could Encode Unique Proteins and Affect Cancer Pathways 121
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 121
Clinical-diagnostic relevance of breast “incidentaloma” detected during 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography: Correlation with radiological imaging and histopathology 121
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials 120
Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives 120
The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients 120
Immediate administration of zoledronic acid reduces aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial 119
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278) 119
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 118
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results 117
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting 117
Tumor infiltrating lymphocytes in triple negative breast cancer and correlations with prognosis 116
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 116
Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study 115
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 113
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer 112
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination 111
Gene expression profiling in breast cancer: A clinical perspective 109
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 109
The promher study: An observational Italian study on adjuvant therapy for her2-positive, pT1a-b pN0 breast cancer 108
Pattern of distant recurrence according to the molecular subtypes identified by immunohistochemistry in women with early breast cancer 106
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? 106
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 106
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke 106
Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives 105
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: Extending endocrine sensitivity 103
Erratum: miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models 102
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer 100
Gli standard oncologici nel Percorso Diagnostico Terapeutico Assistenziale del paziente con carcinoma del colon: Dati del biennio 2009-2010 presso l'UO di Oncologia Clinica dell'AOU di Ferrara 98
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 97
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 96
The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma 92
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 91
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer 90
How to fish a good micro-marker out from a worthless lake: The case of cell-free miR-181a-5p and breast cancer 88
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 88
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 87
Italian cohort of the nivolumab EAP in squamous NSCLC: Efficacy and safety in patients with CNS metastases 87
Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study 86
Pulmonary strongyloidiasis mimicking cancer symptoms: A case of hyperinfection in a patient with metastatic lung cancer 84
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study 84
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 82
null 77
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 76
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study 70
Totale 13.597
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.621
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.621
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.037 0 0 0 0 0 154 56 165 104 254 167 137
2021/2022844 33 48 53 22 26 109 76 42 57 109 48 221
2022/20231.024 116 59 60 112 134 133 49 124 119 11 71 36
2023/2024582 55 70 27 19 42 88 25 52 12 15 19 158
2024/20252.776 70 76 229 119 345 276 154 150 491 275 310 281
2025/20263.625 636 246 567 866 1.179 131 0 0 0 0 0 0
Totale 14.242